Capital investments in production plants represent a significant portion of the cost of new recombinant drugs
Carol A. Ziomek
Advertisement
Carol A. Ziomek, PhD is vice president for development at GTC Biotherapeutics, Inc.
Articles by Carol A. Ziomek
Advertisement
Latest Updated Articles
Production of Recombinant Therapeutic Proteins in the Milk of Transgenic AnimalsPublished: August 1st 2006 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Trends in Formulation eBook October 2025
2
In KPMG's CEO Outlook, AI, Regulatory Demands, and Supply Chain Risk Rank High
3
New Cellevate Nanofiber Microcarriers Aim to Transform Vaccine Manufacturing Processes
4
Analytics, Automation, and Quality Driving the Next Era of Drug Development
5
